ERBB2 and cancer: The bifunctional ligand was conjugated with trastuzumab, Figure 21c, a human epidermal growth factor receptor 2 (HER2) targeting antibody, which selectively targets the HER2 protein overexpressed in particular cancers including 90% of colorectal cancers [126].